Introduction:

Tivoxen 1.34 mg, manufactured by Everest Pharmaceuticals Ltd and supplied by Orio Pharma, is a highly effective targeted therapy used for the treatment of advanced renal cell carcinoma (RCC). Containing Tivozanib, Tivoxen 1.34 mg is a potent inhibitor of vascular endothelial growth factor (VEGF) receptors, which are crucial for the growth and spread of cancer cells. This medication is designed to slow the progression of RCC by inhibiting tumor angiogenesis, offering a significant treatment option for patients with advanced kidney cancer.

Manufacturing Excellence of Everest Pharmaceuticals Ltd.:

Everest Pharmaceuticals Ltd. is dedicated to producing high-quality pharmaceutical products that meet stringent international standards. The development of Tivoxen 1.34 mg reflects Everest’s commitment to advancing cancer treatments through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Tivoxen 1.34 mg is a reliable and effective option for managing advanced renal cell carcinoma.

Mechanism of Action:

Tivoxen 1.34 mg contains Tivozanib, a tyrosine kinase inhibitor that selectively inhibits the VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3). These receptors play a key role in angiogenesis, the process by which tumors develop their own blood supply to fuel growth and metastasis. By blocking these receptors, Tivozanib effectively reduces the blood supply to the tumor, inhibiting its growth and the spread of cancer cells. This targeted action helps to slow disease progression and extend survival in patients with advanced RCC.

Clinical Applications:

Tivoxen 1.34 mg is indicated for the treatment of:

• Advanced Renal Cell Carcinoma (RCC): Tivoxen 1.34 mg is used in adult patients with advanced RCC, particularly in those who have not received prior systemic therapy. It is also used in patients who have progressed on or after prior therapies, offering a new line of treatment in the management of this aggressive cancer.

Clinical studies have shown that Tivozanib is effective in improving progression-free survival in patients with advanced RCC, making it a valuable option in targeted cancer therapy.

Dosage and Administration:

The recommended dosage of Tivoxen 1.34 mg is one capsule taken once daily for 21 days, followed by a 7-day break (a total 28-day cycle). This cycle may be repeated as long as the patient continues to benefit from the treatment. The capsule should be swallowed whole with water, and it can be taken with or without food. It is important for patients to adhere to their healthcare provider’s instructions and follow the prescribed dosing schedule. Regular monitoring of the patient’s health, including liver function and blood pressure, is necessary to assess the response to therapy and manage any potential side effects.

Benefits of Tivoxen 1.34 mg:

• Targeted Cancer Therapy: Tivoxen 1.34 mg provides a precision treatment for patients with advanced RCC, directly targeting the VEGF receptors that drive tumor growth and spread.
• Improved Progression-Free Survival: Clinical evidence shows that Tivoxen 1.34 mg significantly delays disease progression, offering hope for patients with advanced kidney cancer.
• Convenient Oral Administration: The once-daily oral dosing of Tivoxen 1.34 mg ensures ease of use and supports patient adherence to the treatment regimen.
• Well-Tolerated: Tivoxen 1.34 mg is generally well-tolerated, with a safety profile that supports its use in long-term treatment under proper medical supervision.

Supplier: Orio Pharma

Orio Pharma ensures that Tivoxen 1.34 mg is readily available to healthcare providers and patients, offering reliable access to this innovative therapy for advanced RCC. Their commitment to efficient supply and distribution supports effective management of this challenging cancer, helping to improve patient outcomes.

Conclusion:

Tivoxen 1.34 mg (Tivozanib) by Everest Pharmaceuticals Ltd, supplied by Orio Pharma, represents a significant advancement in the treatment of advanced renal cell carcinoma. This targeted therapy offers an effective and convenient option for managing this aggressive form of cancer, improving treatment outcomes and enhancing quality of life. By incorporating Tivoxen 1.34 mg into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for managing advanced RCC, ultimately leading to better health outcomes and extended survival.